source
- Immunotherapy startup Adecto shuts down, citing risk-averse funding climateAdecto Pharmaceuticals, a Boston-based immunotherapy biotech founded in 2014 by Tufts researchers, announced it is closing after 12 years. The company had been developing AD100, a monoclonal antib…
- Sanofi pays Regeneron $1 billion upfront to co-develop four early-stage immunology assetsSanofi has agreed to pay Regeneron an upfront fee of $1 billion to partner on four early‑stage immunology programs, a move intended to capture the success of their joint Dupixent antibody. Dupixen…